Final Results from PUNCH CD3-OLS, an Open-Label Clinical Trial of REBYOTA (Fecal Microbiota Live-jslm) in Patients with Recurrent C. Difficile Infection
Time: 9:30 am
day: Conference Day One
Details:
- Topline results will be presented from the largest (n=697 treated) single study of REBYOTA
- Safety and efficacy will be presented for the study population and subgroups of interest (IBD and Immunosuppressed patients)
- Results provide further evidence that REBYOTA is safe and well tolerated in a variety of patients with recurrent C. diff infection
